Twist Bioscience (TWST) 10-Q 6 May 22 2022 Q2 Quarterly report Financial data

Cover Page

Cover Page - shares	6 Months Ended
	Mar. 31, 2022	May 04, 2022
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2022
Document Transition Report	false
Entity File Number	001-38720
Entity Registrant Name	Twist Bioscience Corporation
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	46-2058888
Entity Address, Address Line One	681 Gateway Blvd
Entity Address, City or Town	South San Francisco
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94080
City Area Code	800
Local Phone Number	719-0671
Title of 12(b) Security	Common Stock
Trading Symbol	TWST
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		56,264,039
Amendment Flag	false
Entity Central Index Key	0001581280
Current Fiscal Year End Date	--09-30
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q2

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (unaudited) - USD ($) $ in Thousands	Mar. 31, 2022	Sep. 30, 2021
Current assets:
Cash and cash equivalents	$ 407,627	$ 465,829
Short-term investments	166,231	12,034
Accounts receivable, net	34,877	28,549
Inventories	44,591	31,800
Prepaid expenses and other current assets	11,049	8,283
Total current assets	664,375	546,495
Long term investments	30,587	0
Property and equipment, net	91,814	44,122
Operating lease right-of-use assets	78,215	61,580
Goodwill	85,678	22,434
Intangible assets, net	62,493	18,262
Restricted cash, non-current	1,572	1,530
Other non-current assets	6,902	7,674
Total assets	1,021,636	702,097
Current liabilities:
Accounts payable	16,815	14,900
Accrued expenses	15,942	6,437
Accrued compensation	21,686	22,327
Current portion of operating lease liability	14,166	8,213
Current portion of long-term debt	0	1,552
Other current liabilities	16,023	9,623
Total current liabilities	84,632	63,052
Operating lease liability, net of current portion	65,496	53,156
Other non-current liabilities	8,147	5,068
Total liabilities	158,275	121,276
Commitments and contingencies
Stockholders’ equity
Common stock, $0.00001 par value—100,000 and 100,000 shares authorized at March 31, 2022 and September 30, 2021, respectively; 56,234 and 49,499 shares issued and outstanding at March 31, 2022 and September 30, 2021, respectively	0	0
Additional paid-in capital	1,580,620	1,190,828
Accumulated other comprehensive income	(475)	546
Accumulated deficit	(716,784)	(610,553)
Total stockholders’ equity	863,361	580,821
Total liabilities and stockholders’ equity	$ 1,021,636	$ 702,097

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares shares in Thousands	Mar. 31, 2022	Sep. 30, 2021
Statement of Financial Position [Abstract]
Common stock, par value (in usd per share)	$ 0.00001	$ 0.00001
Common stock, authorized (in shares)	100,000	100,000
Common stock, issued (in shares)	56,234	49,499
Common stock, outstanding (in shares)	56,234	49,499

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021
Statement of Comprehensive Income [Abstract]
Revenues	$ 48,127	$ 31,204	$ 90,145	$ 59,364
Operating expenses:
Cost of revenues	29,714	19,028	56,770	37,190
Research and development	31,231	15,791	53,861	29,791
Selling, general and administrative	53,998	34,389	105,096	63,181
Change in fair value of contingent considerations and holdbacks	(6,014)	0	(8,840)	0
Total operating expenses	108,929	69,208	206,887	130,162
Loss from operations	(60,802)	(38,004)	(116,742)	(70,798)
Interest income	259	157	412	291
Interest expense	(29)	(95)	(54)	(213)
Other income (expense), net	(245)	84	(401)	8
Loss before income taxes	(60,817)	(37,858)	(116,785)	(70,712)
Benefit from (provision for) income taxes	149	(61)	10,554	(107)
Net loss attributable to common stockholders	(60,668)	(37,919)	(106,231)	(70,819)
Other comprehensive loss:
Change in unrealized gain (loss) on investments	(1,113)	10	(1,389)	1
Foreign currency translation adjustment	275	38	368	102
Comprehensive loss	$ (61,506)	$ (37,871)	$ (107,252)	$ (70,716)
Net loss per share attributable to common stockholders—basic (in usd per share)	$ (1.13)	$ (0.78)	$ (2.06)	$ (1.50)
Net loss per share attributable to common stockholders—diluted (in usd per share)	$ (1.13)	$ (0.78)	$ (2.06)	$ (1.50)
Weighted average shares used in computing net loss per share attributable to common stockholders—basic (in shares)	53,472	48,709	51,673	47,340
Weighted average shares used in computing net loss per share attributable to common stockholders—diluted (in shares)	53,472	48,709	51,673	47,340

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders’ Equity (unaudited) - USD ($) shares in Thousands, $ in Thousands	Total	Common stock	Additional paid-in capital	Accumulated Other comprehensive income	Accumulated deficit
Beginning balance (in shares) at Sep. 30, 2020		45,083
Beginning balance at Sep. 30, 2020	$ 336,262	$ 0	$ 794,630	$ 87	$ (458,455)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock in public offering, net of underwriting discounts and commissions and offering expenses (in shares)		3,136
Issuance of common stock in public offering, net of underwriting discounts and commissions and offering expenses	323,887		323,887
Net exercise of stock warrants (in shares)		22
Vesting of restricted stock units (in shares)		121
Exercise of stock options (in shares)		497
Exercise of stock options	9,137		9,137
Issuance of shares under the employee stock purchase plan (in shares)		49
Issuance of shares under the employee stock purchase plan	2,787		2,787
Repurchases of early exercised stock options (in shares)		(2)
Repurchases of common stock for income tax withholding (in shares)		(46)
Repurchases of common stock for income tax withholding	(5,751)		(5,751)
Stock-based compensation	18,575		18,575
Other comprehensive income	103			103
Net loss	(70,819)				(70,819)
Ending balance (in shares) at Mar. 31, 2021		48,860
Ending balance at Mar. 31, 2021	614,181	$ 0	1,143,265	190	(529,274)
Beginning balance (in shares) at Dec. 31, 2020		48,616
Beginning balance at Dec. 31, 2020	637,952	$ 0	1,129,165	142	(491,355)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Public offering expense adjustment	36		36
Vesting of restricted stock units (in shares)		67
Exercise of stock options (in shares)		152
Exercise of stock options	3,066		3,066
Issuance of shares under the employee stock purchase plan (in shares)		49
Issuance of shares under the employee stock purchase plan	2,787		2,787
Repurchases of early exercised stock options (in shares)		(2)
Repurchases of common stock for income tax withholding (in shares)		(22)
Repurchases of common stock for income tax withholding	(3,341)		(3,341)
Stock-based compensation	11,552		11,552
Other comprehensive income	48			48
Net loss	(37,919)				(37,919)
Ending balance (in shares) at Mar. 31, 2021		48,860
Ending balance at Mar. 31, 2021	614,181	$ 0	1,143,265	190	(529,274)
Beginning balance (in shares) at Sep. 30, 2021		49,499
Beginning balance at Sep. 30, 2021	580,821	$ 0	1,190,828	546	(610,553)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock in public offering, net of underwriting discounts and commissions and offering expenses (in shares)		5,227
Issuance of common stock in public offering, net of underwriting discounts and commissions and offering expenses	269,818		269,818
Vesting of restricted stock units (in shares)		163
Exercise of stock options (in shares)		368
Exercise of stock options	3,934		3,934
Issuance of shares under the employee stock purchase plan (in shares)		50
Issuance of shares under the employee stock purchase plan	2,395		2,395
Repurchases of common stock for income tax withholding (in shares)		(62)
Repurchases of common stock for income tax withholding	(4,050)		(4,050)
Issuance of shares from business acquisition (in shares)		989
Issuance of shares from business acquisition	77,122		77,122
Stock-based compensation	40,573		40,573
Other comprehensive income	(1,021)			(1,021)
Net loss	(106,231)				(106,231)
Ending balance (in shares) at Mar. 31, 2022		56,234
Ending balance at Mar. 31, 2022	863,361	$ 0	1,580,620	(475)	(716,784)
Beginning balance (in shares) at Dec. 31, 2021		50,735
Beginning balance at Dec. 31, 2021	626,178	$ 0	1,281,931	363	(656,116)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock in public offering, net of underwriting discounts and commissions and offering expenses (in shares)		5,227
Issuance of common stock in public offering, net of underwriting discounts and commissions and offering expenses	269,818		269,818
Vesting of restricted stock units (in shares)		100
Exercise of stock options (in shares)		100
Exercise of stock options	896		896
Issuance of shares under the employee stock purchase plan (in shares)		50
Issuance of shares under the employee stock purchase plan	2,395		2,395
Repurchases of common stock for income tax withholding (in shares)		(38)
Repurchases of common stock for income tax withholding	(1,493)		(1,493)
Issuance of shares from business acquisition (in shares)		60
Issuance of shares from business acquisition	4,608		4,608
Stock-based compensation	22,465		22,465
Other comprehensive income	(838)			(838)
Net loss	(60,668)				(60,668)
Ending balance (in shares) at Mar. 31, 2022		56,234
Ending balance at Mar. 31, 2022	$ 863,361	$ 0	$ 1,580,620	$ (475)	$ (716,784)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders’ Equity (unaudited) (Parenthetical) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Mar. 31, 2022	Mar. 31, 2022	Mar. 31, 2021
Statement of Stockholders' Equity [Abstract]
Net of underwriting discounts, commissions and offering expenses	$ 17,682	$ 17,682	$ 21,113

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (unaudited) - USD ($) $ in Thousands	6 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Cash flows from operating activities
Net loss	$ (106,231)	$ (70,819)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization	7,118	4,575
Deferred tax liability	(11,045)	0
Loss on disposal of property and equipment	0	2
Non-cash lease expense	1,609	214
Stock-based compensation	40,573	18,575
Discount accretion on investment securities	790	314
Realized gain on investments	0	(4)
Non-cash interest expense	3	44
Bad debt expense	(180)	417
Amortization of debt discount	4	53
Contingent consideration and holdbacks	(8,840)	0
Write off property and equipment	70	0
Changes in assets and liabilities:
Accounts receivable, net	(3,845)	(1,331)
Inventories	(12,787)	(3,544)
Prepaid expenses and other current assets	(1,407)	(2,731)
Other non-current assets	3,873	(87)
Accounts payable	(762)	3,798
Accrued expenses	1,885	(45)
Accrued compensation	(653)	(38)
Other liabilities	832	1,126
Net cash used in operating activities	(88,993)	(49,481)
Cash flows from investing activities
Purchases of property and equipment	(44,753)	(12,030)
Business acquisition, net of cash acquired	(8,160)	0
Purchases of investments	(217,639)	(58,795)
Proceeds from maturity of investments	30,676	98,494
Net cash (used in) provided by investing activities	(239,876)	27,669
Cash flows from financing activities
Proceeds from exercise of stock options	4,000	9,116
Proceeds from public offerings, net of underwriting discounts, commissions and offering expenses	269,818	323,887
Proceeds from issuance of common stock under employee stock purchase plan	2,395	2,787
Repayments of long-term debt	(1,558)	(1,667)
Repurchases of common stock for income tax withholding	(4,050)	(5,751)
Net cash provided by financing activities	270,605	328,372
Effect of exchange rates on cash, cash equivalents and restricted cash	104	53
Net increase (decrease) in cash, cash equivalents, and restricted cash	(58,160)	306,613
Cash, cash equivalents, and restricted cash at beginning of period	467,359	94,246
Cash, cash equivalents, and restricted cash at end of period	409,199	400,859
Supplemental disclosure of cash flow information
Interest paid	9	109
Income taxes paid, net of refunds	130	1
Non-cash investing and financing activities
Property and equipment additions included in accounts payable and accrued expenses	8,737	197
Operating lease right-of-use assets obtained in exchange for operating lease liabilities	19,494	63
Issuance of common stock in connection with the business acquisition	$ 77,122	$ 0

The Company

The Company	6 Months Ended
	Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
The Company	The Company Twist Bioscience Corporation (the Company) was incorporated in the state of Delaware on February 4, 2013. The Company is a synthetic biology company that has developed a disruptive DNA synthesis platform. DNA is used in many applications across different industries: industrial chemicals/materials, academic, healthcare and food/agriculture. The Company’s fiscal year ends on September 30. The Company has generated net losses in all periods since its inception. As of March 31, 2022, the Company had an accumulated deficit of $716.8 million and has not generated positive cash flows from operations since inception. Losses are expected to continue as the Company continues to invest in product development, manufacturing, and sales and marketing. Since its inception, the Company has received an aggregate of $1,333.7 million in net proceeds from the issuance of equity securities and an aggregate of $13.8 million from debt. Management believes that these proceeds combined with existing cash balances on hand will be sufficient to fund operations for at least one year from the issuance of these consolidated financial statements. However, if the Company needs to obtain additional financing to fund operations beyond this period, there can be no assurance that it will be successful in raising additional financing on terms which are acceptable to the Company. If the Company requires but is unable to obtain additional funding, the Company could be forced to delay, reduce or eliminate some or all of its research and development programs, product portfolio expansion or commercialization efforts, which could adversely affect its business prospects, or the Company may be unable to continue operations. During the three and six months ended March 31, 2022, financial results of the Company were not significantly affected by the COVID-19 pandemic, which continues to have global impact. The Company has considered all information available as of the date of issuance of these financial statements and the Company is not aware of any specific events or circumstances that would require an update to its estimates or judgments, or a revision to the carrying value of its assets or liabilities. These estimates may change as new events occur and additional information becomes available. The extent to which the COVID-19 outbreak affects the Company’s future financial results and operations will depend on future developments which continue to evolve and are difficult to predict, including new information concerning mutations in the SARS-CoV-2 virus, which may make it more contagious, and current or future domestic and international actions to contain it and treat it.

Summary of significant accounti

Summary of significant accounting policies	6 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Summary of significant accounting policies	Summary of significant accounting policies Basis of presentation and use of estimates The accompanying unaudited condensed consolidated financial statements were prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim financial information. Certain information and disclosures normally included in the consolidated financial statements prepared in accordance with GAAP have been condensed or omitted. Accordingly, these unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the related notes included in the Annual Report on Form 10-K for the fiscal year ended September 30, 2021 (the Annual Report on Form 10-K) filed with the Securities and Exchange Commission on November 23, 2021. The condensed consolidated financial statements are unaudited and have been prepared on a basis consistent with that used to prepare the audited annual consolidated financial statements and include, in the opinion of management, all adjustments, consisting of normal and recurring items, necessary for the fair statement of the condensed consolidated financial statements. The condensed consolidated balance sheet at September 30, 2021 is derived from audited consolidated financial statements but does not include all disclosures required by GAAP. The operating results for the three and six months ended March 31, 2022 are not necessarily indicative of the results expected for the full year ending September 30, 2022 or any interim period. The presentation of unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the condensed consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. The Company’s unaudited condensed consolidated financial statements include its wholly owned subsidiaries. The Company consolidates Revelar Biotherapeutics, Inc. (“Revelar”) as a variable interest entity (“VIE”) for which it is the primary beneficiary (see Note 15 “Investment in variable interest entity” for further information). All intercompany balances and accounts are eliminated in consolidation. The following table provides a reconciliation of the Company’s cash and cash equivalents and non-current portion of restricted cash reported within the unaudited condensed consolidated balance sheets that sum to the total cash, cash equivalents and restricted cash shown in the Company’s condensed consolidated statements of cash flows: (in thousands) March 31, September 30, Cash and cash equivalents $ 407,627 $ 465,829 Restricted cash, non-current 1,572 1,530 Total cash, cash equivalents and restricted cash $ 409,199 $ 467,359 Significant accounting policies There have been no material changes in the accounting policies from those disclosed in the audited consolidated financial statements and the related notes included in the Annual Report on Form 10-K other than the following variable interest entities policy. Variable interest entities The Company consolidates a VIE in which the Company is deemed to be the primary beneficiary. An entity is generally a VIE if it meets any of the following criteria: (i) the entity has insufficient equity to finance its activities without additional subordinated financial support from other parties, (ii) the equity investors cannot make significant decisions about the entity’s operations or (iii) the voting rights of some investors are not proportional to their obligations to absorb the expected losses of the entity or receive the expected returns of the entity and substantially all of the entity’s activities involve or are conducted on behalf of the investor with disproportionately few voting rights. The Company periodically makes judgments in determining whether its investees are VIEs and, for each reporting period, the Company assesses whether it is the primary beneficiary of its VIE. As of March 31, 2022, the Company was deemed the primary beneficiary of Revelar. See Note 15 “Investment in variable interest entity.” Recent accounting pronouncements Changes to GAAP are established by the Financial Accounting Standards Board (“FASB”) in the form of accounting standards updates (“ASUs”) to the FASB’s Accounting Standards Codification (“ASC”). The Company considered the applicability and impact of all recent ASUs. ASUs not listed below were assessed and determined to be not applicable to the Company’s consolidated financial position and results of operations. Recent accounting pronouncements adopted In December 2019, the FASB issued ASU 2019 12, Simplifying the Accounting for Income Taxes. The ASU simplifies the accounting for income taxes by eliminating certain exceptions to the guidance in ASC 740, Income Taxes, related to the approach for allocating income tax expense or benefit for the year to continuing operations, discontinued operations, other comprehensive income, and other charges or credits recorded directly to shareholders’ equity; the methodology for calculating income taxes in an interim period; and the recognition of deferred tax liabilities for outside basis differences. The Company adopted this standard effective October 1, 2021. The adoption of ASU 2019 12 did not have an impact on the Company’s consolidated financial statements for either period presented. Recently issued accounting pronouncement not yet adopted In November 2021, the FASB issued ASU 2021 10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance. The amendments in this update require the following annual disclosures about transactions with a government that are accounted for by applying a grant or contribution accounting model. The amendments in this update are effective for all entities within their scope for financial statements issued for annual periods beginning after December 15, 2021. Early application is permitted. The Company is currently evaluating the impact that the adoption of this standard will have on its consolidated financial statements. In June 2016, the FASB issued ASU 2016 13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The new standard requires entities to use the new “expected credit loss” impairment model for most financial assets measured at amortized cost, including trade and other receivables and held-to-maturity debt securities, and modifies the impairment model for available-for-sale debt securities. The standard is effective for the Company for the fiscal year ending September 30, 2024, including interim periods within that fiscal year. Early application

Fair value measurement

Fair value measurement	6 Months Ended
	Mar. 31, 2022
Fair Value Disclosures [Abstract]
Fair value measurement	Fair value measurement The Company assesses the fair value of financial instruments based on the provisions of ASC 820, Fair Value Measurements . ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value: Level 1—Quoted prices in active markets for identical assets or liabilities. Level 2—Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. The Company short-term and long-term investments primarily utilize broker quotes in a non-active market for valuation of its investments. Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as considers counterparty credit risk in its assessment of fair value. As of March 31, 2022, financial assets and liabilities measured and recognized at fair value are as follows: (in thousands) Level 1 Level 2 Level 3 Fair value Assets Money market funds $ 349,277 $ — $ — $ 349,277 Corporate bonds — 29,817 — 29,817 Commercial paper — 54,945 — 54,945 U.S. government treasury bills 112,056 — — 112,056 Total financial assets $ 461,333 $ 84,762 $ — $ 546,095 Liabilities Contingent consideration and holdbacks $ — $ 11,398 $ 5,700 $ 17,098 Total financial liabilities $ — $ 11,398 $ 5,700 $ 17,098 As of September 30, 2021, financial assets and liabilities measured and recognized at fair value are as follows: (in thousands) Level 1 Level 2 Level 3 Fair value Assets Money market funds $ 430,438 $ — $ — $ 430,438 U.S. government treasury bills 12,034 — — 12,034 Total financial assets $ 442,472 $ — $ — $ 442,472 Liabilities Contingent consideration and indemnity holdback $ — $ 9,856 $ — $ 9,856 Total financial liabilities $ — $ 9,856 $ — $ 9,856 As of March 31, 2022 gross unrealized losses for cash equivalents and investments was $1.4 million. As of September 30, 2021, gross unrealized gains and unrealized losses for cash equivalents and investments were not material. As of March 31, 2022, the value of marketable securities with a contractual maturity of less than one year was $166.2 million and the value of marketable securities with a contractual maturity of more than year but less than two years was $30.6 million. As of September 30, 2021, all marketable securities had a contractual maturity of less than one year. The following table provides a reconciliation of beginning and ending balances of the Level 3 financial liabilities during the three months ended March 31, 2022: (in thousands) Total Balance as of September 30, 2021 $ — Contingent consideration – additions 8,500 Change in fair value (2,800) Balance as of March 31, 2022 $ 5,700

Balance sheet components

Balance sheet components	6 Months Ended
	Mar. 31, 2022
Balance Sheet Related Disclosures [Abstract]
Balance sheet components	Balance sheet components The Company’s accounts receivable, net balance consists of the following: (in thousands) March 31, September 30, Trade receivables $ 28,674 $ 26,549 Other receivables 6,356 2,337 Allowance for doubtful accounts (153) (337) Accounts receivable, net $ 34,877 $ 28,549 Inventories consist of the following: (in thousands) March 31, September 30, Raw materials $ 31,975 $ 18,778 Work-in-process 3,048 4,837 Finished goods 9,568 8,185 $ 44,591 $ 31,800 The work-in-process inventory included gross consigned inventory of $1.2 million and $1.9 million as of March 31, 2022 and September 30, 2021, respectively. Other non-current assets The other non-current assets consist of the following: (in thousands) March 31, September 30, Convertible note receivable $ 3,081 $ 3,021 Other non-current assets 3,821 4,653 $ 6,902 $ 7,674 Accrued expenses The accrued expenses consist of the following: (in thousands) March 31, September 30, Professional services fees payable $ 6,163 $ 5,057 Other accrued expenses 9,779 1,380 $ 15,942 $ 6,437 Accrued compensation The accrued compensation consists of the following: (in thousands) March 31, September 30, Accrued vacation $ 5,880 $ 4,643 Accrued bonus 5,838 8,584 Accrued commissions 3,853 3,330 Accrued payroll and related taxes 4,952 4,676 Other accrued compensation 1,163 1,094 $ 21,686 $ 22,327 Other current liabilities The other current liabilities consist of the following: (in thousands) March 31, September 30, Contingent consideration and holdbacks $ 10,004 $ 5,186 Income and sales taxes payable 3,588 2,440 Other current liabilities 2,431 1,997 $ 16,023 $ 9,623 Other non-current liabilities The other non-current liabilities consist of the following: (in thousands) March 31, September 30, Holdback $ 7,093 $ 4,671 Other non current liabilities 1,054 397 $ 8,147 $ 5,068

Goodwill and intangible assets

Goodwill and intangible assets	6 Months Ended
	Mar. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and intangible assets	Goodwill and intangible assets During the six months ended March 31, 2022, goodwill and intangible assets increased by $63.2 million and $46.5 million, respectively, as a result of a business acquisition. See Note 14, “Business acquisition”. Total amortization expense related to intangible assets was $1.4 million for the three months ended March 31, 2022 and less than $0.1 million for the three months ended March 31, 2021. Total amortization expense related to intangible assets was $2.3 million and $0.1 million for the six months ended March 31, 2022 and 2021, respectively. The intangible assets balances are presented below: March 31, 2022 (in thousands, except for years) Weighted average Gross Accumulated Net book Developed Technology 15 $ 50,020 $ (2,745) $ 47,275 Customer Relationships 10 15,210 (792) 14,418 Tradenames & Trademarks 3 900 (100) 800 Total indefinite-lived intangible assets $ 66,130 $ (3,637) $ 62,493 September 30, 2021 (in thousands, except for years) Weighted average Gross Accumulated Net book Developed Technology 16 $ 19,120 $ (1,361) $ 17,759 Customer Relationships 2 510 (7) 503 Total indefinite-lived intangible assets $ 19,630 $ (1,368) $ 18,262

Commitments and contingencies

Commitments and contingencies	6 Months Ended
	Mar. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and contingencies	Commitments and contingencies The Company may be subject to litigation, claims and disputes in the ordinary course of business. There is an inherent risk in any litigation or dispute and no assurance can be given as to the outcome of any claims. Indemnifications In the ordinary course of business, the Company enters into agreements that may include indemnification provisions. Pursuant to such agreements, the Company may indemnify, hold harmless and defend the indemnified parties for losses suffered or incurred by the indemnified party. Some of the provisions will limit losses to those arising from third-party actions. In some cases, the indemnification will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. To date, the Company has not incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. The Company has also entered into indemnification agreements with its directors and officers that may require it to indemnify its directors and officers against liabilities that may arise by reason of their status or service as directors or officers to the fullest extent permitted by corporate law. The Company also has directors’ and officers’ insurance. Leases The Company leases certain of its facilities under non-cancellable operating leases expiring at various dates through 2044. The Company is also responsible for utilities, maintenance, insurance, and property taxes under these leases. Certain leases include options to renew or terminate at the Company’s discretion. The lease terms include periods covered by these options if it is reasonably certain the Company will renew or not terminate. The Company’s lease agreements do not contain any material residual value guarantees or restrictive covenants. Supplemental balance sheet information related to the Company’s operating leases as of March 31, 2022 was the following: (in thousands) March 31, Assets: Operating lease right-of-use asset $ 78,215 Current liabilities: Current portion of operating lease liabilities $ 14,166 Noncurrent liabilities: Operating lease liabilities, net of current portion $ 65,496 Future minimum lease payments under all non-cancelable operating leases that have commenced as of March 31, 2022 are as follows: (in thousands) Operating Years ending September 30: Remainder of 2022 $ 7,140 2023 13,987 2024 13,372 2025 13,706 2026 12,280 Thereafter 96,817 Total minimum lease payments $ 157,302 Less: imputed interest (60,012) Less: tenant improvement allowance (receipt anticipated in 2022) (17,628) Total operating lease liabilities $ 79,662 Less: current portion (14,166) Operating lease liabilities, net of current portion $ 65,496 For the remainder of 2022, future minimum lease payments are comprised of the anticipated receipt of tenant improvement allowances totaling $17.6 million anticipated to be received in 2022, partially offset by non-cancelable operating lease payments of $7.1 million. The statement of cash flows for the six months ended March 31, 2022, include changes in right-of-use assets and operating lease liabilities of $16.6 million and $18.2 million, respectively. For the six months ended March 31, 2021, changes in right-of-use assets and operating lease liabilities were $2.7 million and $2.5 million, respectively. During the three and six months ended March 31, 2022, operating lease expense was $3.9 million and $7.4 million, respectively. Cash payments for amounts included in the measurement of operating lease liabilities were $3.2 million and $6.0 million for the three and six months ended March 31, 2022, respectively. As of March 31, 2022, the weighted-average remaining lease term was 15.5 years and the weighted-average discount rate was 6.45%. On July 28, 2021, the Company entered into a 7-year operating lease for approximately 21,000 square-feet of office space located in South San Francisco, California, to further expand the Company operations. Upon execution of the lease agreement, the Company provided the landlord an approximate $0.2 million security deposit. The Company will pay an initial annual base rent of approximately $1.7 million, which is subject to scheduled 3% annual increases, plus certain operating expenses. The Company has the right to sublease the facility, subject to landlord consent. The lease commenced on October 1, 2021. As of lease commencement date, the total future minimum lease payments under the agreement were $13.1 million. On August 6, 2021, Abveris, which was subsequently acquired by the Company, entered into a 10-year, 5-month operating lease for approximately 22,000 square-feet of office space located in Canton, Massachusetts, to further expand operations. Upon execution of the lease agreement, the Company provided the landlord an approximate $0.6 million irrevocable letter of credit as a security deposit. The Company will pay an initial annual base rent of approximately $1.2 million, which is subject to scheduled 2% annual increases, plus certain operating expenses. The Company has the right to sublease the

Related party transactions

Related party transactions	6 Months Ended
	Mar. 31, 2022
Related Party Transactions [Abstract]
Related party transactions	Related party transactionsDuring the three months ended March 31, 2022 and 2021, the Company purchased raw materials from a related party investor in the amount of $1.7 million and $1.2 million, respectively. During the six months ended March 31, 2022 and 2021, the Company purchased raw materials from a related party investor in the amount of $3.4 million and $2.3 million, respectively. Payable balances and receivable balances with the related party were immaterial as of March 31, 2022 and September 30, 2021.

Income taxes

Income taxes	6 Months Ended
	Mar. 31, 2022
Income Tax Disclosure [Abstract]
Income taxes	Income taxesIn determining quarterly provisions for income taxes, the Company uses the annual estimated effective tax rate applied to the actual year-to-date profit or loss, adjusted for discrete items arising in that quarter. The Company’s annual estimated effective tax rate differs from the U.S. federal statutory rate primarily as a result of state taxes, foreign taxes, and changes in the Company’s valuation allowance against its deferred tax assets. For the three and six months ended March 31, 2022, the Company recorded $0.1 million and $10.6 million income tax benefit due to the deferred tax liability assumed as part of the business acquisition (see Note 14, “Business acquisition”). For the three and six months ended March 31, 2021, the Company recorded an immaterial provision for income taxes.

Warrants

Warrants	6 Months Ended
	Mar. 31, 2022
Warrants and Rights Note Disclosure [Abstract]
Warrants	WarrantsIn connection with its long-term debt agreements, the Company issued 18,854 and 7,531 warrants for its common stock on December 22, 2015 and March 28, 2016, respectively. As of September 30, 2020, there were 26,385 warrants outstanding. In October 2020, a total of 18,854 warrants with an exercise price of $14.85 per common share were exercised for a net 16,051 common shares issued by the Company. In November 2020, a total of 7,531 warrants with an exercise price of $21.24 per common share were exercised for a net 6,041 common shares issued by the Company. There are no outstanding warrants for the Company’s common stock as of March 31, 2022.

Common stock

Common stock	6 Months Ended
	Mar. 31, 2022
Equity [Abstract]
Common stock	Common stockIn December 2020, the Company completed an underwritten public offering of 3,136,362 shares of its common stock at a price to the public of $110.00 per share, including the full exercise of underwriters’ option to purchase an additional 409,090 shares of common stock. The Company received total net proceeds from the offering of $323.9 million, net of estimated underwriting discounts and commissions and offering expenses.In February 2022, the Company completed an underwritten public offering of 5,227,272 shares of its common stock at a price to the public of $55.00 per share, including the full exercise of underwriters’ option to purchase an additional 681,818 shares of common stock. The Company received total net proceeds from the offering of $269.8 million, net of estimated underwriting discounts and commissions and offering expenses.

Stock-based compensation

Stock-based compensation	6 Months Ended
	Mar. 31, 2022
Share-based Payment Arrangement [Abstract]
Stock-based compensation	Stock-based compensation 2018 Equity Incentive Plan On September 1, 2020, the board of directors approved the implementation of a revised annual equity award program for executive officers and senior level employees to be granted as performance-based stock options (PSOs) under the 2018 Plan. The number of PSOs ultimately earned under these awards is calculated based on the achievement of certain total revenue threshold during the fiscal year ending September 30, 2022. The percentage of performance stock options that vest will depend on the board of directors’ determination of total revenue at the end of the performance period and can range from 0% to 150% of the number of options granted. The provisions of the PSO are considered a performance condition, and the effects of that performance condition are not reflected in the grant date fair value of the awards. The Company used the Black-Scholes method to calculate the fair value at the grant date without regard to the vesting condition and will recognize compensation cost for the options that are expected to vest. As of March 31, 2022, the Company determined that 256,665 shares are expected to vest based on the probability of the performance condition that will be achieved under this equity award program. The Company reassesses the probability of the performance condition at each reporting period and adjusts the compensation cost based on the probability assessment. The weighted-average grant date fair value was determined to be $45.18 per share. As of March 31, 2022, the unrecognized compensation costs related to these awards was $2.8 million. The Company expects to recognize those costs over a weighted average period of 0.5 years. Any shares subject to outstanding awards under the 2013 Plan that are canceled or repurchased subsequent to the 2018 Plan’s effective date are returned to the pool of shares reserved for issuance under the 2018 Plan. Awards granted under the 2018 Plan may be non-statutory stock options, stock appreciation rights, restricted stock, restricted stock units, performance shares, and performance units. Activity under the equity incentive plans during the six months ended March 31, 2022 is summarized below: (In thousands, except per share data) Shares Options Weighted Weighted average remaining contractual term Aggregate Outstanding at September 30, 2021 1,728 3,132 $ 27.15 7.3 $ 251,343 Additional shares authorized 1,000 Stock options granted (214) 214 26.14 — — Stock options exercised — (368) 13.05 — — Stock options forfeited 89 (89) 31.96 — — Restricted stock units granted (1,150) — — — — Forfeiture of restricted stock units 67 — — — — Shares withheld for payment of taxes 62 — — — — Outstanding at March 31, 2022 1,582 2,889 $ 28.79 7.0 $ 70,722 Vested or expected to vest at March 31, 2022 — 2,889 $ 28.79 7.0 $ 70,722 Vested and exercisable at March 31, 2022 — 1,739 $ 21.00 6.4 $ 51,266 Total stock-based compensation expense recognized was as follows: Three months ended Six months ended (in thousands) 2022 2021 2022 2021 Cost of revenues $ 1,241 $ 731 $ 2,119 $ 1,218 Research and development 4,838 2,427 8,865 4,428 Selling, general and administrative 16,258 8,394 29,421 12,929 Total stock-based compensation $ 22,337 $ 11,552 $ 40,405 $ 18,575 As of March 31, 2022, there was $22.3 million of total unrecognized compensation cost related to non-vested stock options under the equity incentive plans that is expected to be recognized over a weighted average period of 1.3 years. The weighted-average grant date fair value of stock options granted during the three months ended March 31, 2022 was $73.39 per share. Performance Stock Units Performance stock unit awards (“PSUs”) were granted to certain employees that will vest upon achievement of operational milestones related to the Wilsonville facility and to Company executives that will vest upon achievement of revenue and gross profit metrics as determined by the board. Stock compensation expense for PSUs is recorded over the vesting period based on the grant date fair value of the awards and probability of the achievement of specified performance targets. The grant date fair value is equal to the closing share price of the Company’s common stock on the date of grant. PSUs generally vest over a one The percentage of PSUs that vest will depend on the achievement of specified performance targets at the end of the performance period and can range from 0% to 150% of the number of units granted. Forfeitures of PSUs are recognized as they occur. As of March 31, 2022, the unrecognized compensation costs related to these awards was $22.7 million. The Company expects to recognize those costs over a weighted average period of 2.1 years. Activity under the PSUs during the six months ended March 31, 2022 is summarized below: (in thousands, except per share data) Number of shares Weighted average grant date fair value Weighted average remaining contractual term Aggregate intrinsic value Outstanding at September 30, 2021 10 $ 3.59 2.3 $ 1,016 Performance stock units granted 342 80.31 — — Performance stock units forfeited (1) 3.34 — — Outstanding at March 31, 2022 351 $ 81.21 2.1 $ 17,328 Vested or expected to vest and exercisable at March 31, 2022 351 $ 81.21 2.1 $ 17,328 Restricted Stock Units Restricted stock primarily consists of restricted stock unit awards (RSUs) which have been granted to employees. The value of an RSU award is based on the Company’s stock price on the date of grant. The shares underlying the RSU awards are not issued until the RSUs vest. Upon vesting, each RSU converts into one share of the Company’s common stock. Activity with respect to the Company’s restricted stock units during the six months ended March 31, 2022 was as follows: (in thousands, except per share data) Number Weighted Weighted Aggregate Outstanding at September 30, 2021 698 $ 73.27 2.7 $ 74,613 Restricted stock units granted 807 79.26 — — Restricted stock units vested (164) 72.93 — — Restricted stock units forfeited (66) 73.95 — — Outstanding at March 31, 2022 1,275 $ 85.41 3.2 $ 62,971 Expected to vest at March 31, 2022 1,275 $ 85.41 3.2 $ 62,971 As of March 31, 2022, there was $114.7 million of total unrecognized compensation cost related to these issuances that is expected to be recognized over a weighted average period of 3.1 years. 2018 Employee Stock Purchase Plan On September 26, 2018, the board of directors adopted the 2018 Employee Stock Purchase Plan (the 2018 ESPP). The number of shares reserved for issuance under the 2018 ESPP upon approval was 275,225 shares of the Company’s common stock, and it increases automatically on the first day of each fiscal year, following the fiscal year in which the 2018 ESPP becomes effective, by a number equal to the least of 249,470 shares, 1% of the shares of common stock outstanding at that time, or such number of shares determined by the Company’s board of directors. The number of shares reserved for issuance as at March 31, 2022 is as follows: (In thousands) Shares Outstanding at September 30, 2021 355 Additional shares authorized 249 Shares issued during the period (50) Outstanding at March 31, 2022 554 Subject to any plan limitations, the 2018 ESPP allows eligible service providers (through qualified and non-qualified offerings) to contribute, normally through payroll deductions, up to 15% of their earnings for the purchase of the Company’s common stock at a discounted price per share. The offering periods begin in February and August of each year, except for the initial offering period which commenced with the initial public offering in October 2018 and ended on August 20, 2019. The common shares issuable under the 2018 ESPP were registered pursuant to a registration statement on Form S-8 on November 26, 2018. Unless otherwise determined by the board of directors, the Company’s common stock will be purchased for the accounts of employees participating in the 2018 ESPP at a price per share that is the lesser of 85% of the fair market value of the Company’s common stock on the first trading day of the offering period. During the three and six months ended March 31, 2022 and 2021, activity under the 2018 ESPP was immaterial. Abveris Acquisition As discussed further in Note 14 “Business acquisition”, on December 1, 2021, the Company completed the acquisition of Abveris and granted certain equity awards to new employees. These equity awards include up to 231,876 restricted shares of the Company’s common stock which are issuable based on achievement of the 2022 calendar revenue target, which have an aggregate grant date fair value of $20.1 million. In addition, all employees must remain employed through the payout date, and certain employees have an additional vesting period of up to two years from the acquisition date. The vesting upon achievement of the 2022 calendar revenue target is considered a performance condition, and the effects of that performance condition are not reflected in the grant date fair value of the awards. The Company used the stock price as of December 1, 2021 for the fair value of restricted shares. As of March 31, 2022, the Company determined that 231,876 shares are expected to vest based on the probability of the performance condition that will be achieved under this equity award program. The Company reassesses the probability of the performance condition at each reporting period and adjusts the compensation cost based on the probability assessment. The Company recorded approximately $4.5 million in stock-based compensation expense for the six months ended March 31, 2022 related to these awards. The grant date fair value was determined to be $87.06 per share for restricted shares. As of March 31, 2022, the unrecognized compensation costs related to these awards were $15.7 million. The Company expects to recognize those costs over a weighted average period of 1.4 years.

Net loss per share attributable

Net loss per share attributable to common stockholders	6 Months Ended
	Mar. 31, 2022
Earnings Per Share [Abstract]
Net loss per share attributable to common stockholders	Net loss per share attributable to common stockholders The following table sets forth the computation of the Company’s basic and diluted net loss per share attributable to common stockholders: Three months ended Six months ended (in thousands, except per share data) 2022 2021 2022 2021 Numerator: Net loss attributable to common stockholders $ (60,668) $ (37,919) $ (106,231) $ (70,819) Denominator: Weighted average shares used in computing net loss per share, basic and diluted 53,472 48,709 51,673 47,340 Net loss per share attributable to common stockholders, basic and diluted $ (1.13) $ (0.78) $ (2.06) $ (1.50) The potentially dilutive common shares that were excluded from the calculation of diluted net loss per share because their effect would have been antidilutive for the periods presented are as follows: Three and six months ended March 31, (in thousands) 2022 2021 Shares subject to options to purchase common stock 2,888 3,466 Shares subject to performance-based stock options 257 37 Unvested restricted stock units 1,626 736 Unvested shares of common stock issued upon early exercise of stock options 694 9 Shares subject to employee stock purchase plan 50 23 Total 5,515 4,271

Geographic, product and industr

Geographic, product and industry information	6 Months Ended
	Mar. 31, 2022
Segment Reporting [Abstract]
Geographic, product and industry information	Geographic, product and industry information The table below sets forth revenues by geographic region, based on ship-to destinations. Americas consists of the United States of America, Canada, Mexico and South America; EMEA consists of Europe, the Middle East, and Africa; and APAC consists of Japan, China, South Korea, India, Singapore, Malaysia, and Australia. Three months ended Six months ended (in thousands) 2022 2021 2022 2021 Americas $ 28,458 $ 18,561 $ 51,839 $ 35,896 EMEA 15,204 9,978 29,725 19,036 APAC 4,465 2,665 8,581 4,432 Total $ 48,127 $ 31,204 $ 90,145 $ 59,364 The table below sets forth revenues by products. Three months ended Six months ended (in thousands) 2022 2021 2022 2021 Synthetic genes $ 14,163 $ 9,189 $ 27,688 $ 18,064 Oligo pools 2,308 1,841 5,496 3,351 DNA libraries 1,967 1,940 3,228 3,041 Antibody discovery 6,587 1,283 11,400 2,386 NGS tools 23,102 16,951 42,333 32,522 Total $ 48,127 $ 31,204 $ 90,145 $ 59,364 The table below sets forth revenues by industry. Three months ended Six months ended (in thousands) 2022 2021 2022 2021 Industrial chemicals/materials $ 14,082 $ 8,661 $ 26,800 $ 15,793 Academic research 9,485 5,648 17,372 10,549 Healthcare 24,111 16,564 44,971 32,540 Food/agricultural 449 331 1,002 482 Total $ 48,127 $ 31,204 $ 90,145 $ 59,364

Business acquisition

Business acquisition	6 Months Ended
	Mar. 31, 2022
Business Combination and Asset Acquisition [Abstract]
Business acquisition	Business acquisition On December 1, 2021, the Company acquired all of the outstanding stock of AbX Biologics, Inc. (“Abveris”), a privately-held company providing in vivo antibody discovery services. Abveris offers animal-based antibody discovery and screening services for its customers using the Berkeley Lights Beacon Platform and its proprietary DiversimAb and DivergimAb mouse models, which the Company can humanize using its antibody optimization solution. The acquisition date fair value of the consideration transferred for Abveris was $102.6 million, consisting of cash totaling $9.5 million, 759,601 shares of the Company’s common stock valued at $66.1 million based on the Company’s closing stock price on December 1, 2021, employee stock awards issued to certain Abveris employees valued at $6.4 million, contingent consideration of $8.5 million, holdbacks of $12.8 million, and an estimated net working capital adjustment of $0.7 million. The contingent consideration is subject to the attainment of the calendar year 2022 revenue target. The contingent consideration becomes payable after December 31, 2022 and will be settled in a combination of cash and up to 334,939 shares of the Company’s common stock. The acquisition date fair value of the contingent consideration was based on forecasted revenue of Abveris relative to the 2022 revenue target as well as the Company’s stock price as of December 1, 2021. The Company maintains an indemnity and adjustment holdback for the purposes of providing security against any adjustment to the amounts at closing. The indemnity holdback period extends for 18 months from the anniversary of the closing date. The indemnity holdback will be settled by transferring up to 128,351 shares of the Company’s stock, 15,304 options of the Company’s common stock and an immaterial amount of cash. The fair value of the indemnity holdback was $12.5 million as of the acquisition date. The adjustment holdback will be settled by transferring up to 3,416 shares of the Company’s stock, 408 options of the Company’s common stock and an immaterial amount of cash. The holdback adjustment liability was $0.3 million as of the acquisition date. Additionally, a working capital adjustment of $0.7 million decreased the total purchase price. The purchase price continues to be subject to adjustment for working capital adjustments as allowed under terms of the agreement. Post-combination compensation expense excluded from the purchase price includes employee stock awards issued to certain Abveris employees valued at $41.0 million. This includes awards valued at $17.7 million which vest over a two years service period following the acquisition date and awards valued at $3.2 million with no future vesting requirements, which were deemed accelerated by the Company at the acquisition date and expensed within the three months ended December 31, 2021. Finally, post-combination expense includes awards valued at approximately $20.1 million which vest based on achievement of the calendar year 2022 revenue target and continuing employment through the payout date, and for certain employees, additional continuing employment through the two years anniversary of the acquisition date. This acquisition was accounted for using the acquisition method of accounting in accordance with the business combination guidance in ASC 805. Under the acquisition accounting method, the total estimated purchase price was allocated to the identifiable assets acquired and liabilities assumed based on their fair values. The excess of the purchase price over the net of the acquisition date amounts of the identifiable assets acquired and liabilities assumed has been recorded as goodwill. Management’s estimate of the fair values of the acquired intangible assets at December 1, 2021 is preliminary and subject to change and is based on established and accepted valuation techniques performed with the assistance of third-party valuation specialists. Additional information, which existed as of the acquisition date but is yet unknown to the Company, may become known to the Company during the remainder of the measurement period, which will not exceed twelve months from the acquisition date. Changes to amounts will be recorded as adjustments to the provisional amounts recognized as of the acquisition date and may result in a corresponding adjustment to goodwill in the period in which new information becomes available. The goodwill that arose from the acquisition consists of synergies expected from integrating Abveris into the Company’s operations and customer base. The goodwill recognized is not expected to be deductible for income tax purposes. The following table summarizes the preliminary fair value amounts of the assets acquired and liabilities assumed as of the acquisition date, as well as the purchase consideration: (in thousands) December 1, 2021 Assets acquired Cash and cash equivalents $ 1,306 Accounts receivable 2,309 Other current assets and prepaid expenses 1,654 Property, plant and equipment 1,078 Other non-current assets 2,970 Intangible assets 46,500 Liabilities assumed Current liabilities 3,549 Non-current liabilities 846 Deferred tax liability 10,545 Fair value of assets acquired and liabilities assumed $ 40,877 Goodwill 61,768 Total purchase price $ 102,645 Consideration transferred Cash $ 9,467 Company common stock 72,514 Contingent consideration 8,500 Holdback liabilities 12,838 Net working capital adjustment (674) Fair value of purchase consideration $ 102,645 The following table summarizes the preliminary estimate of the intangible assets as of the acquisition date: (in thousands except for years) Estimated Estimated Fair Developed technology 14 $ 30,900 Customer relationships 10 14,700 Trade name 3 900 Estimated fair value of acquired intangible assets $ 46,500 The Company estimated the fair value of the developed technology intangible asset and a portion of the customer relationships intangible assets using an excess earnings model. An additional portion of the customer relationships intangible assets was valued using the with and without method. The Company estimated the fair value of the trade name intangible asset using a relief from royalty approach. These fair value measurements were based on significant inputs not observable in the market and thus represent a Level 3 measurement. Key assumptions include the level and timing of expected future revenue, conditions and demands specific to each intangible asset over its remaining useful life, and discount rates the Company believes to be consistent with the inherent risks associated with each type of asset, which was approximately 9.6%. The fair value of these intangible assets is primarily affected by the projected revenues, gross margins, operating expenses, the technology obsolescence curve, and the anticipated timing of the projected income associated with each intangible asset coupled with the discount rates used to derive their estimated present values. The Company believes the level and timing of expected future cash flows appropriately reflects market participant assumptions. The Company included the financial results of Abveris in its condensed consolidated financial statements from the date of acquisition. The Company incurred transaction costs related to the acquisition of $1.5 million, which were recorded as an operating expense on the condensed consolidated statements of operations and comprehensive loss for the six months ended March 31, 2022. The following table provides a reconciliation of contingent consideration and holdbacks balances from acquisition date to March 31, 2022: (in thousands) Contingent Holdbacks Total Balance at December 1, 2021 – acquisition date $ 8,500 $ 12,164 $ 20,664 Change in fair value during the period (2,800) (5,266) (8,066) Balance at March 31, 2022 $ 5,700 $ 6,898 $ 12,598 The estimated fair value of the contingent consideration liability decreased as a result of the change in the Company’s stock price from December 31, 2021, and the probability of the attainment of the calendar year 2022 revenue target as calculated using the Monte Carlo simulation model. The estimated fair value of the holdback liability decreased as a result of the change in the Company’s stock price as of December 31, 2021. For the six months ended March 31, 2022, the Company recognized a gain of $8.1 million relating to the change in fair value of acquisition consideration in its condensed consolidated statement of operations. The post-combination effect from net deferred tax liability assumed from the Abveris acquisition also caused a release of the Company’s deferred income tax valuation allowance. The release resulted in an income tax benefit of $10.5 million. The following unaudited pro forma financial information presents the combined results of operations for the Company and Abveris as if the Abveris acquisition had occurred on October 1, 2020. The pro forma information contains the actual operating results of the Company Abveris, adjusted to include the pro forma impact of acquisition, which is primarily additional expense as a result of the amortization of identifiable intangible assets. The unaudited pro forma financial information is prepared for comparative purposes only and does not purport to be indicative of the actual operating results that would have been recorded had the Abveris acquisition actually taken place on October 1, 2020 and should not be taken as indicative of future consolidated operating results. Additionally, the unaudited pro forma financial results do not include any anticipated synergies or other expected benefits from the Abveris acquisition. Three months ended March 31, Six months ended March 31, (in thousands) 2022 2021 2022 2021 Revenues $ 48,127 $ 34,211 $ 92,591 $ 65,113 Net loss attributable to common stockholders $ (60,668) $ (36,129) $ (105,097) $ (67,608) Issuance of contingent consideration for iGenomX acquisition

Investment in variable interest

Investment in variable interest entity	6 Months Ended
	Mar. 31, 2022
Investment in variable interest entity
Investment in variable interest entity	Investment in variable interest entityOn November 1, 2021, the Company contributed certain assets and licensed certain intellectual property rights to the newly formed Revelar Biotherapeutics, Inc. (“Revelar”), an independently operated, new biotechnology company, to develop and commercialize an antibody, discovered and optimized by Twist Biopharma, a division of the Company, that neutralizes all known variants of concern of the SARS-CoV-2 virus in preclinical studies. The Company granted a license to Revelar for the exclusive development of an antibody lead along with a series of back up compounds for the potential treatment of SARS-CoV-2. The Company is eligible to receive success-based milestone payments totaling over $100.0 million for the achievement of key development, regulatory and commercial milestones, as well as mid-single digit royalties on any future net sales. The Company’s receipt of such payments, if any, will depend on Revelar’s ability to successfully develop and commercialize compounds, obtain and maintain necessary regulatory approvals, complete clinical site initiation and finalize clinical trial agreements, none of which can be assured. In addition, Revelar may license up to five additional antibody therapeutics over the next four years, each of which will be subject to additional upfront, milestone and royalty payments to the Company. The Company committed to invest up to $10.0 million in seed funding based on Revelar’s progress in the development of the lead antibody and the potential licensing of additional antibody therapeutics, of which the Company has invested $5.0 million in a simple agreement for future equity (“SAFE”) as of the date of these consolidated financial statements. In exchange for the assignment of certain contractual rights and the license to the antibody, and its back-up compounds, the Company received stock of Revelar amounting to an ownership percentage as of the date of these financial statements of 49.80%, excluding shares and options reserved for future stock awards and further excluding shares that Revelar may issue to the Company upon conversion of its SAFEs. The Company determined that Revelar is a VIE as the entity lacks sufficient equity to finance its activities without additional support. Additionally, the Company determined that it has (a) the power to direct the activities that significantly impact Revelar’s economic performance and (b) the obligation to absorb losses of, and the right to receive benefits from, Revelar that are potentially significant to Revelar. As a result, the Company is deemed to be the primary beneficiary of Revelar and is required to consolidate Revelar in accordance with ASC 810. Revelar incurred a net loss of approximately $3.9 million and $7.0 million for the three and six months ended March 31, 2022, and the decrease in net assets was fully absorbed by the Company. Total assets included on the consolidated balance sheet for Revelar as of March 31, 2022 were $6.5 million, primarily consisting of cash and cash equivalents. Total liabilities included on the consolidated balance sheet for Revelar as of December 31, 2021 were $6.0 million, primarily consisting of accounts payable and accrued expenses. On February 3, 2022, the Company purchased an additional SAFE issued by Revelar for $2.5 million pursuant to the Asset License and Contract Assignment Agreement between the parties. In exchange for the SAFE, the Company obtained the right to receive shares of Revelar issued in a future preferred stock financing.

Summary of significant accoun_2

Summary of significant accounting policies (Policies)	6 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Basis of presentation and use of estimates	Basis of presentation and use of estimates The accompanying unaudited condensed consolidated financial statements were prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim financial information. Certain information and disclosures normally included in the consolidated financial statements prepared in accordance with GAAP have been condensed or omitted. Accordingly, these unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the related notes included in the Annual Report on Form 10-K for the fiscal year ended September 30, 2021 (the Annual Report on Form 10-K) filed with the Securities and Exchange Commission on November 23, 2021. The condensed consolidated financial statements are unaudited and have been prepared on a basis consistent with that used to prepare the audited annual consolidated financial statements and include, in the opinion of management, all adjustments, consisting of normal and recurring items, necessary for the fair statement of the condensed consolidated financial statements. The condensed consolidated balance sheet at September 30, 2021 is derived from audited consolidated financial statements but does not include all disclosures required by GAAP. The operating results for the three and six months ended March 31, 2022 are not necessarily indicative of the results expected for the full year ending September 30, 2022 or any interim period. The presentation of unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the condensed consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. The Company’s unaudited condensed consolidated financial statements include its wholly owned subsidiaries. The Company consolidates Revelar Biotherapeutics, Inc. (“Revelar”) as a variable interest entity (“VIE”) for which it is the primary beneficiary (see Note 15 “Investment in variable interest entity” for further information). All intercompany balances and accounts are eliminated in consolidation.
Variable interest entities	Variable interest entities The Company consolidates a VIE in which the Company is deemed to be the primary beneficiary. An entity is generally a VIE if it meets any of the following criteria: (i) the entity has insufficient equity to finance its activities without additional subordinated financial support from other parties, (ii) the equity investors cannot make significant decisions about the entity’s operations or (iii) the voting rights of some investors are not proportional to their obligations to absorb the expected losses of the entity or receive the expected returns of the entity and substantially all of the entity’s activities involve or are conducted on behalf of the investor with disproportionately few voting rights. The Company periodically makes judgments in determining whether its investees are VIEs and, for each reporting period, the Company assesses whether it is the primary beneficiary of its VIE. As of March 31, 2022, the Company was deemed the primary beneficiary of Revelar. See Note 15 “Investment in variable interest entity.”
Recent accounting pronouncements	Recent accounting pronouncements Changes to GAAP are established by the Financial Accounting Standards Board (“FASB”) in the form of accounting standards updates (“ASUs”) to the FASB’s Accounting Standards Codification (“ASC”). The Company considered the applicability and impact of all recent ASUs. ASUs not listed below were assessed and determined to be not applicable to the Company’s consolidated financial position and results of operations. Recent accounting pronouncements adopted In December 2019, the FASB issued ASU 2019 12, Simplifying the Accounting for Income Taxes. The ASU simplifies the accounting for income taxes by eliminating certain exceptions to the guidance in ASC 740, Income Taxes, related to the approach for allocating income tax expense or benefit for the year to continuing operations, discontinued operations, other comprehensive income, and other charges or credits recorded directly to shareholders’ equity; the methodology for calculating income taxes in an interim period; and the recognition of deferred tax liabilities for outside basis differences. The Company adopted this standard effective October 1, 2021. The adoption of ASU 2019 12 did not have an impact on the Company’s consolidated financial statements for either period presented. Recently issued accounting pronouncement not yet adopted In November 2021, the FASB issued ASU 2021 10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance. The amendments in this update require the following annual disclosures about transactions with a government that are accounted for by applying a grant or contribution accounting model. The amendments in this update are effective for all entities within their scope for financial statements issued for annual periods beginning after December 15, 2021. Early application is permitted. The Company is currently evaluating the impact that the adoption of this standard will have on its consolidated financial statements. In June 2016, the FASB issued ASU 2016 13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The new standard requires entities to use the new “expected credit loss” impairment model for most financial assets measured at amortized cost, including trade and other receivables and held-to-maturity debt securities, and modifies the impairment model for available-for-sale debt securities. The standard is effective for the Company for the fiscal year ending September 30, 2024, including interim periods within that fiscal year. Early application

Summary of significant accoun_3

Summary of significant accounting policies (Tables)	6 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Summary of Cash, Cash Equivalents and Restricted Cash	The following table provides a reconciliation of the Company’s cash and cash equivalents and non-current portion of restricted cash reported within the unaudited condensed consolidated balance sheets that sum to the total cash, cash equivalents and restricted cash shown in the Company’s condensed consolidated statements of cash flows: (in thousands) March 31, September 30, Cash and cash equivalents $ 407,627 $ 465,829 Restricted cash, non-current 1,572 1,530 Total cash, cash equivalents and restricted cash $ 409,199 $ 467,359

Fair value measurement (Tables)

Fair value measurement (Tables)	6 Months Ended
	Mar. 31, 2022
Fair Value Disclosures [Abstract]
Summary of Company's Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis	As of March 31, 2022, financial assets and liabilities measured and recognized at fair value are as follows: (in thousands) Level 1 Level 2 Level 3 Fair value Assets Money market funds $ 349,277 $ — $ — $ 349,277 Corporate bonds — 29,817 — 29,817 Commercial paper — 54,945 — 54,945 U.S. government treasury bills 112,056 — — 112,056 Total financial assets $ 461,333 $ 84,762 $ — $ 546,095 Liabilities Contingent consideration and holdbacks $ — $ 11,398 $ 5,700 $ 17,098 Total financial liabilities $ — $ 11,398 $ 5,700 $ 17,098 As of September 30, 2021, financial assets and liabilities measured and recognized at fair value are as follows: (in thousands) Level 1 Level 2 Level 3 Fair value Assets Money market funds $ 430,438 $ — $ — $ 430,438 U.S. government treasury bills 12,034 — — 12,034 Total financial assets $ 442,472 $ — $ — $ 442,472 Liabilities Contingent consideration and indemnity holdback $ — $ 9,856 $ — $ 9,856 Total financial liabilities $ — $ 9,856 $ — $ 9,856
Summary of Reconciliation of Beginning and Ending Balances of the Level 3 Instruments	The following table provides a reconciliation of beginning and ending balances of the Level 3 financial liabilities during the three months ended March 31, 2022: (in thousands) Total Balance as of September 30, 2021 $ — Contingent consideration – additions 8,500 Change in fair value (2,800) Balance as of March 31, 2022 $ 5,700

Balance sheet components (Table

Balance sheet components (Tables)	6 Months Ended
	Mar. 31, 2022
Balance Sheet Related Disclosures [Abstract]
Summary of Accounts Receivable	The Company’s accounts receivable, net balance consists of the following: (in thousands) March 31, September 30, Trade receivables $ 28,674 $ 26,549 Other receivables 6,356 2,337 Allowance for doubtful accounts (153) (337) Accounts receivable, net $ 34,877 $ 28,549
Summary of Inventories	Inventories consist of the following: (in thousands) March 31, September 30, Raw materials $ 31,975 $ 18,778 Work-in-process 3,048 4,837 Finished goods 9,568 8,185 $ 44,591 $ 31,800
Summary of Other Non-Current Assets	The other non-current assets consist of the following: (in thousands) March 31, September 30, Convertible note receivable $ 3,081 $ 3,021 Other non-current assets 3,821 4,653 $ 6,902 $ 7,674
Summary of Accrued Expenses	The accrued expenses consist of the following: (in thousands) March 31, September 30, Professional services fees payable $ 6,163 $ 5,057 Other accrued expenses 9,779 1,380 $ 15,942 $ 6,437
Summary of Accrued Compensation	The accrued compensation consists of the following: (in thousands) March 31, September 30, Accrued vacation $ 5,880 $ 4,643 Accrued bonus 5,838 8,584 Accrued commissions 3,853 3,330 Accrued payroll and related taxes 4,952 4,676 Other accrued compensation 1,163 1,094 $ 21,686 $ 22,327
Summary of Other Current Liabilities	The other current liabilities consist of the following: (in thousands) March 31, September 30, Contingent consideration and holdbacks $ 10,004 $ 5,186 Income and sales taxes payable 3,588 2,440 Other current liabilities 2,431 1,997 $ 16,023 $ 9,623
Summary of Noncurrent Liabilities	The other non-current liabilities consist of the following: (in thousands) March 31, September 30, Holdback $ 7,093 $ 4,671 Other non current liabilities 1,054 397 $ 8,147 $ 5,068

Goodwill and intangible assets

Goodwill and intangible assets (Tables)	6 Months Ended
	Mar. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Summary of Intangible Assets	The intangible assets balances are presented below: March 31, 2022 (in thousands, except for years) Weighted average Gross Accumulated Net book Developed Technology 15 $ 50,020 $ (2,745) $ 47,275 Customer Relationships 10 15,210 (792) 14,418 Tradenames & Trademarks 3 900 (100) 800 Total indefinite-lived intangible assets $ 66,130 $ (3,637) $ 62,493 September 30, 2021 (in thousands, except for years) Weighted average Gross Accumulated Net book Developed Technology 16 $ 19,120 $ (1,361) $ 17,759 Customer Relationships 2 510 (7) 503 Total indefinite-lived intangible assets $ 19,630 $ (1,368) $ 18,262

Commitments and contingencies (

Commitments and contingencies (Tables)	6 Months Ended
	Mar. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Schedule of Supplemental Balance Sheet Information Relating to Companies Operating Lease	Supplemental balance sheet information related to the Company’s operating leases as of March 31, 2022 was the following: (in thousands) March 31, Assets: Operating lease right-of-use asset $ 78,215 Current liabilities: Current portion of operating lease liabilities $ 14,166 Noncurrent liabilities: Operating lease liabilities, net of current portion $ 65,496
Schedule of Future Minimum Rental Payments for Operating Leases	Future minimum lease payments under all non-cancelable operating leases that have commenced as of March 31, 2022 are as follows: (in thousands) Operating Years ending September 30: Remainder of 2022 $ 7,140 2023 13,987 2024 13,372 2025 13,706 2026 12,280 Thereafter 96,817 Total minimum lease payments $ 157,302 Less: imputed interest (60,012) Less: tenant improvement allowance (receipt anticipated in 2022) (17,628) Total operating lease liabilities $ 79,662 Less: current portion (14,166) Operating lease liabilities, net of current portion $ 65,496

Stock-based compensation (Table

Stock-based compensation (Tables)	6 Months Ended
	Mar. 31, 2022
Share-based Payment Arrangement [Abstract]
Schedule of Activity Under the Equity Incentive Plans	Activity under the equity incentive plans during the six months ended March 31, 2022 is summarized below: (In thousands, except per share data) Shares Options Weighted Weighted average remaining contractual term Aggregate Outstanding at September 30, 2021 1,728 3,132 $ 27.15 7.3 $ 251,343 Additional shares authorized 1,000 Stock options granted (214) 214 26.14 — — Stock options exercised — (368) 13.05 — — Stock options forfeited 89 (89) 31.96 — — Restricted stock units granted (1,150) — — — — Forfeiture of restricted stock units 67 — — — — Shares withheld for payment of taxes 62 — — — — Outstanding at March 31, 2022 1,582 2,889 $ 28.79 7.0 $ 70,722 Vested or expected to vest at March 31, 2022 — 2,889 $ 28.79 7.0 $ 70,722 Vested and exercisable at March 31, 2022 — 1,739 $ 21.00 6.4 $ 51,266
Schedule of Stock-Based Compensation Expenses	Total stock-based compensation expense recognized was as follows: Three months ended Six months ended (in thousands) 2022 2021 2022 2021 Cost of revenues $ 1,241 $ 731 $ 2,119 $ 1,218 Research and development 4,838 2,427 8,865 4,428 Selling, general and administrative 16,258 8,394 29,421 12,929 Total stock-based compensation $ 22,337 $ 11,552 $ 40,405 $ 18,575
Schedule of Nonvested Performance Stock Units Activity	Activity under the PSUs during the six months ended March 31, 2022 is summarized below: (in thousands, except per share data) Number of shares Weighted average grant date fair value Weighted average remaining contractual term Aggregate intrinsic value Outstanding at September 30, 2021 10 $ 3.59 2.3 $ 1,016 Performance stock units granted 342 80.31 — — Performance stock units forfeited (1) 3.34 — — Outstanding at March 31, 2022 351 $ 81.21 2.1 $ 17,328 Vested or expected to vest and exercisable at March 31, 2022 351 $ 81.21 2.1 $ 17,328
Schedule of Nonvested Restricted Stock Units Activity	Activity with respect to the Company’s restricted stock units during the six months ended March 31, 2022 was as follows: (in thousands, except per share data) Number Weighted Weighted Aggregate Outstanding at September 30, 2021 698 $ 73.27 2.7 $ 74,613 Restricted stock units granted 807 79.26 — — Restricted stock units vested (164) 72.93 — — Restricted stock units forfeited (66) 73.95 — — Outstanding at March 31, 2022 1,275 $ 85.41 3.2 $ 62,971 Expected to vest at March 31, 2022 1,275 $ 85.41 3.2 $ 62,971
Summary of Stock Option Valuation Assumptions	The number of shares reserved for issuance as at March 31, 2022 is as follows: (In thousands) Shares Outstanding at September 30, 2021 355 Additional shares authorized 249 Shares issued during the period (50) Outstanding at March 31, 2022 554

Net loss per share attributab_2

Net loss per share attributable to common stockholders (Tables)	6 Months Ended
	Mar. 31, 2022
Earnings Per Share [Abstract]
Computation of the Company's Basic and Diluted Net Loss Per Share Attributable to Common Stockholders	The following table sets forth the computation of the Company’s basic and diluted net loss per share attributable to common stockholders: Three months ended Six months ended (in thousands, except per share data) 2022 2021 2022 2021 Numerator: Net loss attributable to common stockholders $ (60,668) $ (37,919) $ (106,231) $ (70,819) Denominator: Weighted average shares used in computing net loss per share, basic and diluted 53,472 48,709 51,673 47,340 Net loss per share attributable to common stockholders, basic and diluted $ (1.13) $ (0.78) $ (2.06) $ (1.50)
Summary of Calculation of Diluted Net Loss Per Share	The potentially dilutive common shares that were excluded from the calculation of diluted net loss per share because their effect would have been antidilutive for the periods presented are as follows: Three and six months ended March 31, (in thousands) 2022 2021 Shares subject to options to purchase common stock 2,888 3,466 Shares subject to performance-based stock options 257 37 Unvested restricted stock units 1,626 736 Unvested shares of common stock issued upon early exercise of stock options 694 9 Shares subject to employee stock purchase plan 50 23 Total 5,515 4,271

Geographic, product and indus_2

Geographic, product and industry information (Tables)	6 Months Ended
	Mar. 31, 2022
Segment Reporting [Abstract]
Summary of Revenue by Geographic Region	The table below sets forth revenues by geographic region, based on ship-to destinations. Americas consists of the United States of America, Canada, Mexico and South America; EMEA consists of Europe, the Middle East, and Africa; and APAC consists of Japan, China, South Korea, India, Singapore, Malaysia, and Australia. Three months ended Six months ended (in thousands) 2022 2021 2022 2021 Americas $ 28,458 $ 18,561 $ 51,839 $ 35,896 EMEA 15,204 9,978 29,725 19,036 APAC 4,465 2,665 8,581 4,432 Total $ 48,127 $ 31,204 $ 90,145 $ 59,364
Summary of Revenue by Product	The table below sets forth revenues by products. Three months ended Six months ended (in thousands) 2022 2021 2022 2021 Synthetic genes $ 14,163 $ 9,189 $ 27,688 $ 18,064 Oligo pools 2,308 1,841 5,496 3,351 DNA libraries 1,967 1,940 3,228 3,041 Antibody discovery 6,587 1,283 11,400 2,386 NGS tools 23,102 16,951 42,333 32,522 Total $ 48,127 $ 31,204 $ 90,145 $ 59,364
Summary of Revenue by Industry	The table below sets forth revenues by industry. Three months ended Six months ended (in thousands) 2022 2021 2022 2021 Industrial chemicals/materials $ 14,082 $ 8,661 $ 26,800 $ 15,793 Academic research 9,485 5,648 17,372 10,549 Healthcare 24,111 16,564 44,971 32,540 Food/agricultural 449 331 1,002 482 Total $ 48,127 $ 31,204 $ 90,145 $ 59,364

Business acquisition (Tables)

Business acquisition (Tables)	6 Months Ended
	Mar. 31, 2022
Business Combination and Asset Acquisition [Abstract]
Summary of Preliminary Fair Value Amounts of Assets Acquired and Liabilities Assumed	The following table summarizes the preliminary fair value amounts of the assets acquired and liabilities assumed as of the acquisition date, as well as the purchase consideration: (in thousands) December 1, 2021 Assets acquired Cash and cash equivalents $ 1,306 Accounts receivable 2,309 Other current assets and prepaid expenses 1,654 Property, plant and equipment 1,078 Other non-current assets 2,970 Intangible assets 46,500 Liabilities assumed Current liabilities 3,549 Non-current liabilities 846 Deferred tax liability 10,545 Fair value of assets acquired and liabilities assumed $ 40,877 Goodwill 61,768 Total purchase price $ 102,645 Consideration transferred Cash $ 9,467 Company common stock 72,514 Contingent consideration 8,500 Holdback liabilities 12,838 Net working capital adjustment (674) Fair value of purchase consideration $ 102,645
Summary of Preliminary Estimate of Intangible Assets	The following table summarizes the preliminary estimate of the intangible assets as of the acquisition date: (in thousands except for years) Estimated Estimated Fair Developed technology 14 $ 30,900 Customer relationships 10 14,700 Trade name 3 900 Estimated fair value of acquired intangible assets $ 46,500
Schedule of Reconciliation of Contingent Consideration	The following table provides a reconciliation of contingent consideration and holdbacks balances from acquisition date to March 31, 2022: (in thousands) Contingent Holdbacks Total Balance at December 1, 2021 – acquisition date $ 8,500 $ 12,164 $ 20,664 Change in fair value during the period (2,800) (5,266) (8,066) Balance at March 31, 2022 $ 5,700 $ 6,898 $ 12,598
Summary of Pro Forma Information	Three months ended March 31, Six months ended March 31, (in thousands) 2022 2021 2022 2021 Revenues $ 48,127 $ 34,211 $ 92,591 $ 65,113 Net loss attributable to common stockholders $ (60,668) $ (36,129) $ (105,097) $ (67,608)

The Company - (Detail)

The Company - (Detail) - USD ($) $ in Thousands	6 Months Ended
	Mar. 31, 2022	Sep. 30, 2021
Class of Warrant or Right [Line Items]
Accumulated deficit	$ 716,784	$ 610,553
Subsequent Public Offering
Class of Warrant or Right [Line Items]
Proceeds of underwritten public offering common stock	1,333,700
Proceeds from issuance of debt	$ 13,800

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Summary of Cash, Cash Equivalents and Restricted Cash (Detail) - USD ($) $ in Thousands	Mar. 31, 2022	Sep. 30, 2021	Mar. 31, 2021	Sep. 30, 2020
Accounting Policies [Abstract]
Cash and cash equivalents	$ 407,627	$ 465,829
Restricted cash, non-current	1,572	1,530
Total cash, cash equivalents and restricted cash	$ 409,199	$ 467,359	$ 400,859	$ 94,246

Fair Value Measurement - Summar

Fair Value Measurement - Summary of Company's Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail) - USD ($) $ in Thousands	Mar. 31, 2022	Sep. 30, 2021
Assets
Total financial assets	$ 546,095	$ 442,472
Liabilities
Total financial liabilities	17,098	9,856
Money market funds
Assets
Total financial assets	349,277	430,438
Corporate bonds
Assets
Total financial assets	29,817
Commercial paper
Assets
Total financial assets	54,945
U.S. government treasury bills
Assets
Total financial assets	112,056	12,034
Contingent consideration and indemnity holdback
Liabilities
Total financial liabilities	17,098	9,856
Level 1
Assets
Total financial assets	461,333	442,472
Liabilities
Total financial liabilities	0	0
Level 1 | Money market funds
Assets
Total financial assets	349,277	430,438
Level 1 | Corporate bonds
Assets
Total financial assets	0
Level 1 | Commercial paper
Assets
Total financial assets	0
Level 1 | U.S. government treasury bills
Assets
Total financial assets	112,056	12,034
Level 1 | Contingent consideration and indemnity holdback
Liabilities
Total financial liabilities	0	0
Level 2
Assets
Total financial assets	84,762	0
Liabilities
Total financial liabilities	11,398	9,856
Level 2 | Money market funds
Assets
Total financial assets	0	0
Level 2 | Corporate bonds
Assets
Total financial assets	29,817
Level 2 | Commercial paper
Assets
Total financial assets	54,945
Level 2 | U.S. government treasury bills
Assets
Total financial assets	0	0
Level 2 | Contingent consideration and indemnity holdback
Liabilities
Total financial liabilities	11,398	9,856
Level 3
Assets
Total financial assets	0	0
Liabilities
Total financial liabilities	5,700	0
Level 3 | Money market funds
Assets
Total financial assets	0	0
Level 3 | Corporate bonds
Assets
Total financial assets	0
Level 3 | Commercial paper
Assets
Total financial assets	0
Level 3 | U.S. government treasury bills
Assets
Total financial assets	0	0
Level 3 | Contingent consideration and indemnity holdback
Liabilities
Total financial liabilities	$ 5,700	$ 0

Fair Value Measurement - Summ_2

Fair Value Measurement - Summary of Reconciliation of Beginning and Ending Balances of the Level 3 Instruments (Detail) $ in Thousands	6 Months Ended
	Mar. 31, 2022USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance as of September 30, 2021	$ 0
Contingent consideration – additions	8,500
Change in fair value	(2,800)
Balance as of March 31, 2022	$ 5,700

Fair value measurement - Narrat

Fair value measurement - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021
Fair Value Disclosures [Abstract]
Change in unrealized gain (loss) on investments	$ (1,113)	$ 10	$ (1,389)	$ 1
Securities with maturity in remainder of year	166,200		166,200
Securities with maturity greater than one year but less than two	$ 30,600		$ 30,600

Balance sheet components - Rece

Balance sheet components - Receivable (Detail) - USD ($) $ in Thousands	Mar. 31, 2022	Sep. 30, 2021
Balance Sheet Related Disclosures [Abstract]
Trade receivables	$ 28,674	$ 26,549
Other receivables	6,356	2,337
Allowance for doubtful accounts	(153)	(337)
Accounts receivable, net	$ 34,877	$ 28,549

Balance sheet components - Inve

Balance sheet components - Inventory (Detail) - USD ($) $ in Thousands	Mar. 31, 2022	Sep. 30, 2021
Balance Sheet Related Disclosures [Abstract]
Raw materials	$ 31,975	$ 18,778
Work-in-process	3,048	4,837
Finished goods	9,568	8,185
Total inventories	$ 44,591	$ 31,800

Balance sheet components - Narr

Balance sheet components - Narrative (Details) - USD ($) $ in Millions	Mar. 31, 2022	Sep. 30, 2021
Balance Sheet Related Disclosures [Abstract]
Work-in-process inventory included gross consigned	$ 1.2	$ 1.9

Balance sheet components - Othe

Balance sheet components - Other non-current assets (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Sep. 30, 2021
Balance Sheet Related Disclosures [Abstract]
Convertible note receivable	$ 3,081	$ 3,021
Other non-current assets	3,821	4,653
Other non-current assets	$ 6,902	$ 7,674

Balance sheet components - Accr

Balance sheet components - Accrued expenses (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Sep. 30, 2021
Balance Sheet Related Disclosures [Abstract]
Professional services fees payable	$ 6,163	$ 5,057
Other accrued expenses	9,779	1,380
Accrued expenses	$ 15,942	$ 6,437

Balance sheet components - Ac_2

Balance sheet components - Accrued compensation (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Sep. 30, 2021
Balance Sheet Related Disclosures [Abstract]
Accrued vacation	$ 5,880	$ 4,643
Accrued bonus	5,838	8,584
Accrued commissions	3,853	3,330
Accrued payroll and related taxes	4,952	4,676
Other accrued compensation	1,163	1,094
Accrued compensation	$ 21,686	$ 22,327

Balance sheet components - Ot_2

Balance sheet components - Other current liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Sep. 30, 2021
Balance Sheet Related Disclosures [Abstract]
Contingent consideration and holdbacks	$ 10,004	$ 5,186
Income and sales taxes payable	3,588	2,440
Other current liabilities	2,431	1,997
Other current liabilities	$ 16,023	$ 9,623

Balance sheet components - Ot_3

Balance sheet components - Other non current liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Sep. 30, 2021
Balance Sheet Related Disclosures [Abstract]
Holdback	$ 7,093	$ 4,671
Other non current liabilities	1,054	397
Other non-current liabilities	$ 8,147	$ 5,068

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets - Goodwill (Detail) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021
Goodwill And Intangible Assets [Line Items]
Total amortization expense related to intangible assets	$ 1.4		$ 2.3
iGenomX
Goodwill And Intangible Assets [Line Items]
Increase in goodwill			63.2
Increase in intangible assets			$ 46.5
Maximum
Goodwill And Intangible Assets [Line Items]
Total amortization expense related to intangible assets		$ 0.1		$ 0.1

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets - Intangible Assets Balances (Detail) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Mar. 31, 2022	Sep. 30, 2021
Acquired Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	$ 66,130	$ 19,630
Accumulated amortization	(3,637)	(1,368)
Net book value	$ 62,493	$ 18,262
Developed Technology
Acquired Finite-Lived Intangible Assets [Line Items]
Weighted average Amortization period in years	15 years	16 years
Gross carrying amount	$ 50,020	$ 19,120
Accumulated amortization	(2,745)	(1,361)
Net book value	$ 47,275	$ 17,759
Customer Relationships
Acquired Finite-Lived Intangible Assets [Line Items]
Weighted average Amortization period in years	10 years	2 years
Gross carrying amount	$ 15,210	$ 510
Accumulated amortization	(792)	(7)
Net book value	$ 14,418	$ 503
Tradenames & Trademarks
Acquired Finite-Lived Intangible Assets [Line Items]
Weighted average Amortization period in years	3 years
Gross carrying amount	$ 900
Accumulated amortization	(100)
Net book value	$ 800

Commitments and contingencies -

Commitments and contingencies - Operating Leases On Balance Sheet (Detail) - USD ($) $ in Thousands	Mar. 31, 2022	Sep. 30, 2021
Assets:
Operating lease right-of-use assets	$ 78,215	$ 61,580
Current liabilities:
Current portion of operating lease liability	14,166	8,213
Noncurrent liabilities:
Operating lease liability, net of current portion	$ 65,496	$ 53,156

Commitments and contingencies_2

Commitments and contingencies - Minimum Rental Payments (Detail) - USD ($) $ in Thousands	Mar. 31, 2022	Sep. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
Remainder of 2022	$ 7,140
2023	13,987
2024	13,372
2025	13,706
2026	12,280
Thereafter	96,817
Total minimum lease payments	157,302
Less: imputed interest	(60,012)
Less: tenant improvement allowance (receipt anticipated in 2022)	(17,628)
Total operating lease liabilities	79,662
Less: current portion	(14,166)	$ (8,213)
Operating lease liability, net of current portion	$ 65,496	$ 53,156

Commitments and contingencies_3

Commitments and contingencies - Lease Contracts (Detail) ft² in Thousands, $ in Thousands	Aug. 06, 2021USD ($)ft²	Jul. 28, 2021USD ($)ft²	Mar. 31, 2022USD ($)	Mar. 31, 2022USD ($)	Mar. 31, 2021USD ($)
Other Commitments [Line Items]
Tenant improvements			$ 17,600	$ 17,600
Remainder of 2022			7,140	7,140
Change in right-of-use asset				16,600	$ 2,700
Change in operating lease liabilities.				18,200	2,500
Operating lease expense			3,900	7,400
Operating lease payments			$ 3,200	$ 6,000
Lease weighted-average remaining lease term			15 years 6 months	15 years 6 months
Lease weighted average discount rate			6.45%	6.45%
Future minimum payments			$ 157,302	$ 157,302
South San Francisco, California
Other Commitments [Line Items]
Operating lease term		7 years
Operating lease area | ft²		21
Operating lease security deposit with the lessor		$ 200
Initial annual base rent		$ 1,700
Operating lease base rent annual percentage increase		3.00%
Future minimum payments					13,100
Canton, Massachusetts
Other Commitments [Line Items]
Operating lease term	10 years 5 months
Operating lease area | ft²	22
Operating lease security deposit with the lessor	$ 600
Initial annual base rent	$ 1,200
Operating lease base rent annual percentage increase	2.00%
Future minimum payments					$ 13,200

Related Party Transactions - (D

Related Party Transactions - (Detail) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021
Affiliated Entity
Related Party Transaction [Line Items]
Raw materials purchased from related party investor	$ 1.7	$ 1.2	$ 3.4	$ 2.3

Income taxes (Detail)

Income taxes (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021
Income Tax Disclosure [Abstract]
Income tax benefit, due to deferred tax liability as part of business acquisition	$ 100,000	$ 0	$ 10,600,000	$ 0

Warrants - (Detail)

Warrants - (Detail) - $ / shares	Mar. 28, 2016	Dec. 22, 2015	Nov. 30, 2020	Oct. 31, 2020	Mar. 31, 2022	Sep. 30, 2020
Warrants and Rights Note Disclosure [Abstract]
Class of warrants or rights number of warrants issued during the period (in shares)	7,531	18,854
Class of warrants or rights outstanding (in shares)					0	26,385
Number of warrants exercised (in shares)			7,531	18,854
Exercise price per share (in usd per share)			$ 21.24	$ 14.85
Common stock issued for cashless exercise (in shares)			6,041	16,051

Common stock - (Detail)

Common stock - (Detail) - USD ($) $ / shares in Units, $ in Millions	1 Months Ended
	Feb. 28, 2022	Dec. 31, 2020
Subsequent Public Offering
Class of Stock [Line Items]
Sale of stock, shares issued (in shares)	5,227,272	3,136,362
Sale of stock, share price (in usd per share)	$ 55	$ 110
Sale of stock, consideration received		$ 323.9
Over-Allotment Option
Class of Stock [Line Items]
Sale of stock, shares issued (in shares)	681,818	409,090
Sale of stock, consideration received	$ 269.8

Stock-based compensation - Addi

Stock-based compensation - Additional information (Detail) - USD ($) $ / shares in Units, $ in Millions	Sep. 01, 2020	Sep. 26, 2018	Mar. 31, 2022	Sep. 30, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized stock-based compensation expense, period for recognition			1 year 3 months 18 days
Unrecognized compensation cost, stock options			$ 22.3
Weighted average grant date fair value of stock options granted (in usd per share)			$ 73.39
Aggregate number of common stock shares reserved for issuance			554,000	355,000
2018 ESPP
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate number of common stock shares reserved for issuance		275,225
Minimum annual increase in share reserved for issuance		249,470
Annual automatic Increase in share reserved for issuance (as a percent)		1.00%
Percentage of payroll deduction to purchase common stock		15.00%
ESPP eligible employee common stock purchase price ratio		85.00%
Performance Stock Option | 2018 Equity Incentive Plan | Executive Officers and Senior Level Employees
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares expected to vest			256,665
Share based compensation by share based payment arrangement equity instruments other than options non vested outstanding grant date fair value (in usd per share)			$ 45.18
Share based compensation by share based payment arrangement equity instruments other than options unrecognized compensation			$ 2.8
Unrecognized stock-based compensation expense, period for recognition			6 months
Performance Stock Option | 2018 Equity Incentive Plan | Minimum | Executive Officers and Senior Level Employees
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of PSUs that may vest based on performance	0.00%
Performance Stock Option | 2018 Equity Incentive Plan | Maximum | Executive Officers and Senior Level Employees
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of PSUs that may vest based on performance	150.00%
Performance Stock Unit
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation by share based payment arrangement equity instruments other than options non vested outstanding grant date fair value (in usd per share)			$ 81.21	$ 3.59
Share based compensation by share based payment arrangement equity instruments other than options unrecognized compensation			$ 22.7
Unrecognized stock-based compensation expense, period for recognition			2 years 1 month 6 days
Performance Stock Unit | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of PSUs that may vest based on performance			0.00%
Vesting period			1 year
Performance Stock Unit | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of PSUs that may vest based on performance			150.00%
Vesting period			2 years
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation by share based payment arrangement equity instruments other than options non vested outstanding grant date fair value (in usd per share)			$ 85.41	$ 73.27
Restricted Stock Units (RSUs) | 2018 ESPP
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized stock-based compensation expense, period for recognition			3 years 1 month 6 days
Unrecognized compensation cost, stock options			$ 114.7

Stock-based compensation - Acti

Stock-based compensation - Activity Under The Equity Incentive Plans (Detail) $ / shares in Units, shares in Thousands, $ in Thousands	6 Months Ended	12 Months Ended
	Mar. 31, 2022USD ($)$ / sharesshares	Sep. 30, 2021USD ($)$ / sharesshares
Shares available
Additional shares authorized (in shares)	249
2018 Equity Incentive Plan
Shares available
Beginning balance (in shares)	1,728
Additional shares authorized (in shares)	1,000
Stock options granted (in shares)	(214)
Stock options forfeited (in shares)	89
Restricted stock units granted (in shares)	(1,150)
Forfeiture of restricted stock units (in shares)	67
Shares withheld for payment of taxes (in shares)	62
Ending balance (in shares)	1,582	1,728
Options outstanding
Beginning balance (in shares)	3,132
Stock options granted (in shares)	214
Stock options exercised (in shares)	(368)
Stock options forfeited (in shares)	(89)
Ending balance (in shares)	2,889	3,132
Vested or expected to vest (in shares)	2,889
Vested and exercisable (in shares)	1,739
Weighted average exercise price per share
Beginning balance (in usd per share) | $ / shares	$ 27.15
Stock options granted (in usd per share) | $ / shares	26.14
Stock options exercised (in usd per share) | $ / shares	13.05
Stock options forfeited (in usd per share) | $ / shares	31.96
Ending balance (in usd per share) | $ / shares	28.79	$ 27.15
Vested or expected to vest (in usd per share) | $ / shares	28.79
Vested and exercisable (in usd per share) | $ / shares	$ 21
Weighted average remaining contractual term (years)
Weighted average remaining contractual term, Outstanding	7 years	7 years 3 months 18 days
Weighted average remaining contractual term, Vested or expected to vest	7 years
Weighted average remaining contractual term, Vested and exercisable	6 years 4 months 24 days
Aggregate intrinsic value
Aggregate intrinsic value, Outstanding | $	$ 70,722	$ 251,343
Aggregate intrinsic value, Vested or expected to vest | $	70,722
Aggregate intrinsic value, Vested and exercisable | $	$ 51,266

Stock-based compensation - Expe

Stock-based compensation - Expense (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock based compensation expense	$ 22,337	$ 11,552	$ 40,405	$ 18,575
Cost of revenues
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock based compensation expense	1,241	731	2,119	1,218
Research and development
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock based compensation expense	4,838	2,427	8,865	4,428
Selling, general and administrative
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock based compensation expense	$ 16,258	$ 8,394	$ 29,421	$ 12,929

Stock-based compensation - Summ

Stock-based compensation - Summary of PSU Activity (Details) - Performance Stock Unit - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	6 Months Ended	12 Months Ended
	Mar. 31, 2022	Sep. 30, 2021
Number of shares
Beginning balance (in shares)	10
Equity awards restricted shares	342
Forfeited (in shares)	(1)
Ending balance (in shares)	351	10
Expected to vest (in shares)	351
Weighted average grant date fair value per share
Beginning balance (in usd per share)	$ 3.59
Granted (in usd per share)	80.31
Forfeited (in usd per share)	3.34
Ending balance (in usd per share)	81.21	$ 3.59
Expected to vest (in usd per share)	$ 81.21
Weighted average remaining contractual term (years)
Weighted average remaining contractual term, Outstanding	2 years 1 month 6 days	2 years 3 months 18 days
Weighted average remaining contractual term, Expected to vest	2 years 1 month 6 days
Aggregate Intrinsic Value
Aggregate intrinsic value, Outstanding	$ 17,328	$ 1,016
Aggregate intrinsic value, Expected to vest	$ 17,328

Stock-based compensation - Rest

Stock-based compensation - Restricted Stock Units Activity (Detail) - Restricted Stock Units (RSUs) $ / shares in Units, shares in Thousands, $ in Thousands	6 Months Ended	12 Months Ended
	Mar. 31, 2022USD ($)$ / sharesshares	Sep. 30, 2021USD ($)$ / sharesshares
Number of Shares
Beginning balance (in shares) | shares	698
Granted (in shares) | shares	807
Vested (in shares) | shares	(164)
Forfeited (in shares) | shares	(66)
Ending balance (in shares) | shares	1,275	698
Expected to vest (in shares) | shares	1,275
Weighted average grant date fair value per share
Beginning balance (in usd per share) | $ / shares	$ 73.27
Granted (in usd per share) | $ / shares	79.26
Vested (in usd per share) | $ / shares	72.93
Forfeited (in usd per share) | $ / shares	73.95
Ending balance (in usd per share) | $ / shares	85.41	$ 73.27
Expected to vest (in usd per share) | $ / shares	$ 85.41
Weighted average remaining contractual term (years)
Weighted average remaining contractual term, Outstanding	3 years 2 months 12 days	2 years 8 months 12 days
Weighted average remaining contractual term, Expected to vest	3 years 2 months 12 days
Aggregate Intrinsic Value
Aggregate intrinsic value, Outstanding | $	$ 62,971	$ 74,613
Aggregate intrinsic value, Expected to vest | $	$ 62,971

Stock-based compensation - Rese

Stock-based compensation - Reserved For Issuance (Detail) shares in Thousands	6 Months Ended
	Mar. 31, 2022shares
Share-Based Compensation Arrangement By Share-based Payment Award, Outstanding [Roll Forward]
Beginning balance (in shares)	355
Additional shares authorized (in shares)	249
Shares issued during the period (in shares)	(50)
Ending balance (in shares)	554

Stock-based compensation - Abve

Stock-based compensation - Abveris Acquisition (Detail) - USD ($) $ / shares in Units, $ in Thousands	Dec. 01, 2021	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock based compensation expense		$ 22,337	$ 11,552	$ 40,405	$ 18,575
Recognize cost weighted average period				1 year 3 months 18 days
Abveris
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Awards aggregate fair value	$ 20,100
Vesting period	2 years
Stock based compensation expense				$ 4,500
Unrecognized compensation cost		$ 15,700		$ 15,700
Recognize cost weighted average period				1 year 4 months 24 days
Abveris | Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Equity awards restricted shares	231,876
Shares expected to vest		231,876		231,876
Granted (in usd per share)				$ 87.06

Net loss per share attributab_3

Net loss per share attributable to common stockholders - Computation (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021
Numerator:
Net loss attributable to common stockholders	$ (60,668)	$ (37,919)	$ (106,231)	$ (70,819)
Denominator:
Weighted average shares used in computing net loss per share, basic (in shares)	53,472	48,709	51,673	47,340
Weighted average shares used in computing net loss per share, diluted (in shares)	53,472	48,709	51,673	47,340
Net loss per share attributable to common stockholders—basic (in usd per share)	$ (1.13)	$ (0.78)	$ (2.06)	$ (1.50)
Net loss per share attributable to common stockholders, diluted (in usd per share)	$ (1.13)	$ (0.78)	$ (2.06)	$ (1.50)

Net loss per share attributab_4

Net loss per share attributable to common stockholders - Anti-dilutive (Detail) - shares shares in Thousands	3 Months Ended		6 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share amount (in shares)	5,515	4,271	5,515	4,271
Shares subject to options to purchase common stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share amount (in shares)	2,888	3,466	2,888	3,466
Shares subject to performance-based stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share amount (in shares)	257	37	257	37
Unvested restricted stock units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share amount (in shares)	1,626	736	1,626	736
Unvested shares of common stock issued upon early exercise of stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share amount (in shares)	694	9	694	9
Shares subject to employee stock purchase plan
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share amount (in shares)	50	23	50	23

Geographic, product and indus_3

Geographic, product and industry information - Geographic Region (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021
Segment Reporting Information [Line Items]
Revenue	$ 48,127	$ 31,204	$ 90,145	$ 59,364
Americas
Segment Reporting Information [Line Items]
Revenue	28,458	18,561	51,839	35,896
EMEA
Segment Reporting Information [Line Items]
Revenue	15,204	9,978	29,725	19,036
APAC
Segment Reporting Information [Line Items]
Revenue	$ 4,465	$ 2,665	$ 8,581	$ 4,432

Geographic, product and indus_4

Geographic, product and industry information - By Product (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021
Segment Reporting Information [Line Items]
Revenue	$ 48,127	$ 31,204	$ 90,145	$ 59,364
Synthetic genes
Segment Reporting Information [Line Items]
Revenue	14,163	9,189	27,688	18,064
Oligo pools
Segment Reporting Information [Line Items]
Revenue	2,308	1,841	5,496	3,351
DNA libraries
Segment Reporting Information [Line Items]
Revenue	1,967	1,940	3,228	3,041
Antibody discovery
Segment Reporting Information [Line Items]
Revenue	6,587	1,283	11,400	2,386
NGS tools
Segment Reporting Information [Line Items]
Revenue	$ 23,102	$ 16,951	$ 42,333	$ 32,522

Geographic, product and indus_5

Geographic, product and industry information - By Industry (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021
Segment Reporting Information [Line Items]
Revenue	$ 48,127	$ 31,204	$ 90,145	$ 59,364
Industrial chemicals/materials
Segment Reporting Information [Line Items]
Revenue	14,082	8,661	26,800	15,793
Academic research
Segment Reporting Information [Line Items]
Revenue	9,485	5,648	17,372	10,549
Healthcare
Segment Reporting Information [Line Items]
Revenue	24,111	16,564	44,971	32,540
Food/agricultural
Segment Reporting Information [Line Items]
Revenue	$ 449	$ 331	$ 1,002	$ 482

Business acquisition - Narrativ

Business acquisition - Narrative (Details) - USD ($) $ in Thousands	Dec. 01, 2021	Jan. 31, 2022	Dec. 31, 2021	Dec. 31, 2021	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021
Business Acquisition [Line Items]
Income tax benefit					$ (149)	$ 61	$ (10,554)	$ 107
Abveris
Business Acquisition [Line Items]
Fair value of consideration transferred	$ 102,645
Cash consideration	$ 9,467
Equity (in shares)	759,601
Common stock	$ 66,100
Options consisderation	6,400
Contingent consideration	8,500
Indemnity holdbacks	12,800
Net working capital adjustment	$ 674
Contingent consideration, shares issuable up to (in shares)	334,939
Indemnity holdbacks period	18 months
Indemnity holdback shares (in shares)	128,351
Indemnity holdback options (in shares)	15,304
Indemnity holdback consideration	$ 12,500
Adjustment holdback shares (in shares)	3,416
Adjustment holdback options (in shares)	408
Value of adjustment holdback	$ 300
Post combination compensation expenses includes employee stock awards			$ 41,000
Vesting period from acquisition date	2 years
Discount rate					9.60%		9.60%
Transaction costs							$ 1,500
Change in fair value during the period				$ 8,066			(8,100)
Income tax benefit							$ 10,500
Company common stock	$ 72,514
Abveris | Awards with vesting requirements
Business Acquisition [Line Items]
Post combination compensation expenses includes employee stock awards			$ 17,700
Vesting period from acquisition date			2 years
Abveris | Awards without vesting requirements
Business Acquisition [Line Items]
Post combination compensation expenses includes employee stock awards			$ 3,200
Abveris | Performance Shares
Business Acquisition [Line Items]
Post combination compensation expenses includes employee stock awards			$ 20,100
iGenomX
Business Acquisition [Line Items]
Contingent consideration (in shares)			59,190
Company common stock		$ 4,600

Business acquisition - Assets a

Business acquisition - Assets acquired and liabilities assumed (Details) - USD ($) $ in Thousands	Dec. 01, 2021	Mar. 31, 2022	Sep. 30, 2021
Liabilities assumed
Goodwill		$ 85,678	$ 22,434
Abveris
Assets acquired
Cash and cash equivalents	$ 1,306
Accounts receivable	2,309
Other current assets and prepaid expenses	1,654
Property, plant and equipment	1,078
Other non-current assets	2,970
Intangible assets	46,500
Liabilities assumed
Current liabilities	3,549
Non-current liabilities	846
Deferred tax liability	10,545
Fair value of assets acquired and liabilities assumed	40,877
Goodwill	61,768
Total purchase price	102,645
Consideration transferred
Cash	9,467
Equity interests issued	72,514
Contingent consideration	8,500
Holdback liabilities	12,838
Net working capital adjustment	(674)
Fair value of purchase consideration	$ 102,645

Business acquisition - Prelimin

Business acquisition - Preliminary estimate of the intangible assets (Details) - Abveris $ in Thousands	Dec. 01, 2021USD ($)
Business Acquisition [Line Items]
Estimated Fair Value	$ 46,500
Developed Technology
Business Acquisition [Line Items]
Estimated Weighted Average Useful Lives in Years	14 years
Estimated Fair Value	$ 30,900
Customer Relationships
Business Acquisition [Line Items]
Estimated Weighted Average Useful Lives in Years	10 years
Estimated Fair Value	$ 14,700
Trade name
Business Acquisition [Line Items]
Estimated Weighted Average Useful Lives in Years	3 years
Estimated Fair Value	$ 900

Business acquisition - Change i

Business acquisition - Change in contingent consideration (Details) - Abveris - USD ($) $ in Thousands	1 Months Ended	6 Months Ended
	Dec. 31, 2021	Mar. 31, 2022
Business Combination, Contingent Consideration Arrangements, Change In Amount Of Contingent Consideration, Liability [Roll Forward]
Balance at December 1, 2021 – acquisition date	$ 20,664
Change in fair value during the period	(8,066)	$ 8,100
Balance at March 31, 2022	12,598
Contingent consideration
Business Combination, Contingent Consideration Arrangements, Change In Amount Of Contingent Consideration, Liability [Roll Forward]
Balance at December 1, 2021 – acquisition date	8,500
Change in fair value during the period	(2,800)
Balance at March 31, 2022	5,700
Holdbacks
Business Combination, Contingent Consideration Arrangements, Change In Amount Of Contingent Consideration, Liability [Roll Forward]
Balance at December 1, 2021 – acquisition date	12,164
Change in fair value during the period	(5,266)
Balance at March 31, 2022	$ 6,898

Business acquisition - Pro form

Business acquisition - Pro forma financial results (Details) - Abveris - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021
Business Acquisition [Line Items]
Revenue	$ 48,127	$ 34,211	$ 92,591	$ 65,113
Net loss attributable to common stockholders	$ (60,668)	$ (36,129)	$ (105,097)	$ (67,608)

Investment in variable intere_2

Investment in variable interest entity (Details) $ in Thousands	Apr. 06, 2022USD ($)	Feb. 03, 2022USD ($)	Nov. 01, 2021USD ($)item	Mar. 31, 2022USD ($)	Mar. 31, 2022USD ($)	Dec. 31, 2021USD ($)	Sep. 30, 2021USD ($)
Variable Interest Entity [Line Items]
Total assets				$ 1,021,636	$ 1,021,636		$ 702,097
Total liabilities				158,275	158,275		$ 121,276
Revelar
Variable Interest Entity [Line Items]
Additional SAFE issued		$ 2,500
Revelar | Subsequent events
Variable Interest Entity [Line Items]
Additional SAFE issued	$ 2,500
Variable Interest Entity, Primary Beneficiary | Revelar
Variable Interest Entity [Line Items]
Eligible success based payments to be received			$ 100,000
Additional antibody therapeutics that may license | item			5
Period of additional antibody therapeutics that maybe licensed			4 years
Investment amount			$ 5,000
Ownership percentage			49.80%
Loss absorbed by reporting entity				3,900	7,000
Total assets				$ 6,500	$ 6,500
Total liabilities						$ 6,000
Variable Interest Entity, Primary Beneficiary | Revelar | Maximum
Variable Interest Entity [Line Items]
Investment amount			$ 10,000